Key Details
The Reform: Amendments to the Medical Devices Rules, 2017 to simplify regulatory requirements for medical-device manufacturers and importers.
Core Objective: To reduce compliance burden, improve transparency and shorten approval timelines while maintaining standards of quality, safety and performance.
Simpler Sterilisation Compliance: Manufacturers can outsource sterilisation to a licensed facility without obtaining a separate loan licence. The sterilisation facility’s licence number must appear on the device label.
Standardised Testing Charges: A new fee schedule introduces uniform charges for specified medical-device tests, improving predictability and reducing variation across testing laboratories.
Faster Access for EU-Approved Devices: The European Union has been added to the recognised jurisdictions for waiver of clinical-investigation requirements for eligible medical devices without predicate devices.
Three Reforms Address Different Regulatory Bottlenecks
The Ministry of Health and Family Welfare has introduced amendments to the Medical Devices Rules, 2017 aimed at simplifying compliance, improving predictability and facilitating timely access to medical technologies.
The reforms concentrate on three areas:
simplifying outsourced sterilisation requirements;
introducing uniform testing charges; and
expanding the list of recognised foreign regulatory jurisdictions for eligible devices.
Together, these changes seek to reduce duplication in the regulatory process rather than dilute safety requirements.
Outsourced Sterilisation Becomes Easier
Medical-device manufacturers that do not maintain their own sterilisation facilities can now use another facility that already holds a valid licence for carrying out the sterilisation process.
Earlier, manufacturers outsourcing this activity were required to obtain a separate loan licence. Removing this additional requirement can reduce documentation, approval time and compliance costs, particularly for manufacturers that rely on specialised external facilities.
At the same time, regulatory traceability is retained. The licence number of the external sterilisation facility must be stated on the device label, and this requirement becomes mandatory six months after notification.
The change is therefore significant for smaller and specialised manufacturers: they can access professional sterilisation infrastructure without necessarily replicating the facility internally, while regulators and users retain information on where the process was undertaken.
Standard Testing Fees Improve Cost Predictability
A second major reform is the introduction of a Ninth Schedule specifying fees for medical-device testing and evaluation.
Some prescribed charges include:
Implantation test: ₹5,000
Sterility test: ₹2,000
Syringes and needles: ₹1,000
Surgical sutures: ₹3,000
Condoms and intrauterine devices: ₹2,500 each
Bacterial endotoxin testing: ₹3,000 for qualitative and ₹4,500 for quantitative testing
Tests not included in the schedule may be priced by the concerned testing laboratory, while prescribed charges will increase automatically by 5% annually.
The significance of this reform lies in giving manufacturers and importers greater certainty over regulatory testing costs and reducing variations in charges across laboratories.
EU Recognition Could Shorten Market-Entry Timelines
The Health Ministry announcement also states that the European Union is being added to the jurisdictions recognised under Rule 63 for waiver of clinical-investigation requirements for eligible medical devices without predicate devices.
The framework already recognises the United States, United Kingdom, Australia, Canada and Japan. Eligible medical devices without predicate devices that have already received approval in the EU may now qualify for waiver of clinical-investigation requirements in India.
This reform reflects greater international regulatory convergence: rather than automatically duplicating evidence-generation requirements, Indian regulation can rely on assessments from recognised stringent regulatory systems where appropriate.
The measure also signals greater international regulatory convergence, allowing India to rely more effectively on assessments undertaken by established regulatory systems where appropriate.
What is a Predicate Device?
A predicate device is an already marketed medical device that can serve as a reference for assessing a new device with similar intended use, design or performance. Devices without such a reference may require additional clinical evidence.
Policy Relevance
Lower compliance costs without removing oversight: Using already licensed sterilisation facilities can reduce procedural duplication while maintaining traceability through mandatory labelling.
Greater certainty for manufacturers: Standard testing fees make regulatory costs more predictable, which is particularly useful for smaller medical-device firms navigating approval processes.
Faster access to innovative devices: Recognition of approvals from additional stringent jurisdictions can reduce unnecessary repetition of clinical investigations and potentially shorten market-entry timelines.
International regulatory convergence is increasing: Greater reliance on credible overseas regulatory assessments can make India's system more interoperable with major medical-device markets.
Implementation quality remains important: Faster approvals and lower compliance requirements must continue to be accompanied by effective post-market surveillance and enforcement of quality, safety and performance standards.
Follow The Full Update Here: Gazette Notification: Amendments to Medical Devices Rules, 2017